Drug Profile
Interleukin-12 gene therapy - Valentis
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute; University of Pennsylvania; Valentis
- Class Antineoplastics; Cytokine genes; Gene therapies; Immunotherapies; Interleukins
- Mechanism of Action Interleukin 12 stimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Head and neck cancer; Malignant melanoma
Most Recent Events
- 19 Sep 2006 Discontinued - Phase-II for Head and neck cancer in USA (Intratumoural)
- 19 Sep 2006 Discontinued - Phase-II for Malignant melanoma in USA (unspecified route)
- 15 Jan 2002 Valentis reduces its preclinical product development efforts and suspends its programs in oncology